- $450.45m
- -$20.00m
- $2.37m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.96 | ||
| Price to Tang. Book | 0.96 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 190.06 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -16.51% | ||
| Return on Equity | -26.45% | ||
| Operating Margin | -3281.18% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | 1.21 | 2.38 | 2.37 | 1.5 | 1.52 | 39.84% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Upstream Bio, Inc. is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The Company is developing verekitug, the only known antagonist in clinical development, that targets the receptor for thymic stromal lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. It has advanced this highly potent monoclonal antibody into separate phase II trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and plans to initiate development in chronic obstructive pulmonary disease. TSLP is a member of a class of epithelial cytokines, also including IL-25 and IL-33, commonly referred to as alarmins. TSLP is primarily produced by epithelial cells, especially in the lung, gastrointestinal tract and skin.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- April 21st, 2021
- Public Since
- October 11th, 2024
- No. of Shareholders
- 28
- No. of Employees
- 52
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 53,688,703
- Address
- 890 Winter Street, Suite 200, WALTHAM, 02451
- Web
- https://upstreambio.com/
- Phone
- +1 7812082466
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for UPB
Similar to UPB
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
What is the Upstream Bio share price?
As of Today at 23:53 UTC, shares in Upstream Bio are trading at $8.39. This share price information is delayed by 15 minutes.
How has the Upstream Bio share price performed this year?
Shares in Upstream Bio last closed at $8.39 and the price had moved by over the past 365 days. In terms of relative price strength the Upstream Bio share price has matched the S&P500 Index by over the past year.
What are the analyst and broker recommendations for Upstream Bio?
The overall consensus recommendation for Upstream Bio is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Upstream Bio dividend yield?
Upstream Bio does not currently pay a dividend.
Does Upstream Bio pay a dividend?
Upstream Bio does not currently pay a dividend.
When does Upstream Bio next pay dividends?
Upstream Bio does not currently pay a dividend.
How do I buy Upstream Bio shares?
To buy shares in Upstream Bio you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Upstream Bio?
As of the previous close price of $8.39, shares in Upstream Bio had a market capitalisation of $450.45m.
Where are Upstream Bio shares listed?
Here are the trading details for Upstream Bio:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: UPB
What kind of share is Upstream Bio?
Based on an overall assessment of its quality, value and momentum Upstream Bio is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Upstream Bio share price forecast for 2025?
The analyst consensus target price for shares in Upstream Bio is $56.50. That is 573.42% above the last closing price of $8.39.
Analysts covering Upstream Bio currently have a consensus Earnings Per Share (EPS) forecast of -$2.40 for the next financial year.
Find out moreWhat is the trend in the Upstream Bio share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Upstream Bio. Over the past six months, its share price has underperformed the S&P500 Index by -64.71%.
As of the last closing price of $8.39, shares in Upstream Bio were trading -42.65% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Upstream Bio PE Ratio?
The Upstream Bio PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $8.39.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Upstream Bio?
We do not have data on Upstream Bio's directors